$144.24
0.62%
Downside
Day's Volatility :3.08%
Upside
2.48%
61.7%
Downside
52 Weeks Volatility :68.11%
Upside
16.74%
Period | Sarepta Therapeutics, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 14.59% | 6.5% | 0.0% |
6 Months | 24.28% | 7.1% | 0.0% |
1 Year | 41.71% | 9.8% | 0.0% |
3 Years | 121.63% | 14.2% | -20.2% |
Market Capitalization | 14.1B |
Book Value | $10.17 |
Earnings Per Share (EPS) | 0.42 |
PE Ratio | 355.95 |
PEG Ratio | 159.25 |
Wall Street Target Price | 196.69 |
Profit Margin | 1.2% |
Operating Margin TTM | 8.44% |
Return On Assets TTM | -1.89% |
Return On Equity TTM | 2.02% |
Revenue TTM | 1.4B |
Revenue Per Share TTM | 14.95 |
Quarterly Revenue Growth YOY | 63.1% |
Gross Profit TTM | -78.1M |
EBITDA | -53.0M |
Diluted Eps TTM | 0.42 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 3.65 |
EPS Estimate Next Year | 12.07 |
EPS Estimate Current Quarter | -0.07 |
EPS Estimate Next Quarter | -0.13 |
What analysts predicted
Upside of 36.36%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 301.0M | ↑ 94.74% |
Net Income | -361.9M | ↑ 614.01% |
Net Profit Margin | -120.22% | ↓ 87.43% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 380.8M | ↑ 26.51% |
Net Income | -715.1M | ↑ 97.58% |
Net Profit Margin | -187.77% | ↓ 67.55% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 540.1M | ↑ 41.82% |
Net Income | -554.1M | ↓ 22.51% |
Net Profit Margin | -102.6% | ↑ 85.17% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 701.9M | ↑ 29.96% |
Net Income | -418.8M | ↓ 24.43% |
Net Profit Margin | -59.66% | ↑ 42.94% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 933.0M | ↑ 32.93% |
Net Income | -703.5M | ↑ 67.99% |
Net Profit Margin | -75.4% | ↓ 15.74% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 1.2B | ↑ 33.26% |
Net Income | -536.0M | ↓ 23.81% |
Net Profit Margin | -43.11% | ↑ 32.29% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 258.4M | ↑ 12.23% |
Net Income | -109.2M | ↓ 57.61% |
Net Profit Margin | -42.27% | ↑ 69.66% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 253.5M | ↓ 1.91% |
Net Income | -516.8M | ↑ 373.03% |
Net Profit Margin | -203.85% | ↓ 161.58% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 261.2M | ↑ 3.05% |
Net Income | -23.9M | ↓ 95.37% |
Net Profit Margin | -9.16% | ↑ 194.69% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 331.8M | ↑ 27.02% |
Net Income | -40.9M | ↑ 71.0% |
Net Profit Margin | -12.34% | ↓ 3.18% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 396.8M | ↑ 19.58% |
Net Income | 45.7M | ↓ 211.53% |
Net Profit Margin | 11.51% | ↑ 23.85% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 413.5M | ↑ 4.2% |
Net Income | 36.1M | ↓ 20.89% |
Net Profit Margin | 8.74% | ↓ 2.77% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 1.6B | ↑ 25.54% |
Total Liabilities | 609.8M | ↑ 17.55% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 1.8B | ↑ 11.01% |
Total Liabilities | 1.0B | ↑ 64.75% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 3.0B | ↑ 63.74% |
Total Liabilities | 2.2B | ↑ 121.27% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 3.1B | ↑ 5.47% |
Total Liabilities | 2.2B | ↓ 0.13% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 3.1B | ↓ 0.62% |
Total Liabilities | 2.7B | ↑ 23.58% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 3.3B | ↑ 4.35% |
Total Liabilities | 2.4B | ↓ 12.33% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 3.1B | ↓ 0.88% |
Total Liabilities | 2.7B | ↑ 0.66% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.1B | ↓ 2.19% |
Total Liabilities | 2.3B | ↓ 14.45% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.1B | ↑ 2.16% |
Total Liabilities | 2.4B | ↑ 1.6% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.1B | ↓ 0.52% |
Total Liabilities | 2.3B | ↓ 1.64% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.3B | ↑ 4.98% |
Total Liabilities | 2.4B | ↑ 2.55% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 3.2B | ↓ 1.23% |
Total Liabilities | 2.3B | ↓ 5.91% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -388.7M | ↑ 67.53% |
Investing Cash Flow | -370.5M | ↑ 107.19% |
Financing Cash Flow | 530.2M | ↓ 40.3% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -456.5M | ↑ 17.45% |
Investing Cash Flow | 286.7M | ↓ 177.39% |
Financing Cash Flow | 642.6M | ↑ 21.2% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 107.5M | ↓ 123.54% |
Investing Cash Flow | -121.7M | ↓ 142.45% |
Financing Cash Flow | 682.3M | ↑ 6.19% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -443.2M | ↓ 512.38% |
Investing Cash Flow | 495.4M | ↓ 507.01% |
Financing Cash Flow | 561.6M | ↓ 17.7% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -325.3M | ↓ 26.59% |
Investing Cash Flow | -1.0B | ↓ 311.32% |
Financing Cash Flow | 232.5M | ↓ 58.6% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -92.4M | ↑ 42.22% |
Investing Cash Flow | 9.8M | ↓ 48.76% |
Financing Cash Flow | 10.7M | ↓ 95.03% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -209.4M | ↑ 126.64% |
Investing Cash Flow | 12.5M | ↑ 27.52% |
Financing Cash Flow | 101.8M | ↑ 847.02% |
Sell
Neutral
Buy
Sarepta Therapeutics, Inc. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Sarepta Therapeutics, Inc. | -5.96% | 24.28% | 41.71% | 121.63% | -1.21% |
![]() Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
![]() Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
![]() Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
![]() Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Sarepta Therapeutics, Inc. | 355.95 | 355.95 | 159.25 | 3.65 | 0.02 | -0.02 | NA | 10.17 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
![]() Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
![]() Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
![]() Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Sarepta Therapeutics, Inc. | Buy | $14.1B | -1.21% | 355.95 | 1.2% |
![]() Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
![]() Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Sarepta Therapeutics, Inc.
Revenue is up for the last 5 quarters, 253.5M → 413.46M (in $), with an average increase of 11.2% per quarter
Netprofit is down for the last 2 quarters, 45.65M → 36.11M (in $), with an average decrease of 20.9% per quarter
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 19.9%
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 64.9%
Vanguard Group Inc
BlackRock Inc
HHG PLC
Capital Research & Mgmt Co - Division 3
venBio Select Advisor LLC
Wellington Management Company LLP
sarepta therapeutics is a biopharmaceutical company focused on the discovery and development of unique rna-targeted therapeutics for the treatment of rare, infectious and other diseases. the company is primarily focused on rapidly advancing the development of its potentially disease-modifying dmd drug candidates, including its lead dmd product candidate, eteplirsen, designed to skip exon 51. sarepta is also developing therapeutics for the treatment of infectious diseases, such as drug-resistant bacteria and other rare human diseases. for more information, please visit us at www.sarepta.com.
Organization | Sarepta Therapeutics, Inc. |
Employees | 1314 |
CEO | Mr. Douglas S. Ingram Esq. |
Industry | Health Technology |
Cubesmart
$144.24
-2.25%
Iqvia Holdings Inc.
$144.24
-2.25%
Microsectors Travel 3x Inlev
$144.24
-2.25%
Jack Henry & Associates Inc.
$144.24
-2.25%
Packaging Corporation Of America
$144.24
-2.25%
Cognizant Technology Solutions Corp.
$144.24
-2.25%
Synopsys Inc.
$144.24
-2.25%
Targa Resources Corp.
$144.24
-2.25%
Parker-hannifin Corporation
$144.24
-2.25%